MAZE vs NVAX: stock comparison and AI forecast
Maze Therapeutics, Inc. (MAZE) and Novavax Inc (NVAX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
MAZE Maze Therapeutics, Inc.
- Price
- $30.37 +12.8% · 6M
- Market Cap
- $1.69B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
NVAX Novavax Inc
- Market Cap
- $1.66B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
- NO CURRENT FORECAST
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- MAZE and NVAX have similar market capitalizations ($1.69B and $1.66B).
- NVAX turns -59.9% of its revenue into net income, against -334.0% for MAZE.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | MAZE | NVAX |
|---|---|---|
| Market Cap | $1.69B | $1.66B |
| P/B Ratio | 3.72x | – |
| EPS | $-1.89 | $-1.29 |
| Book Value/Share | $8.16 | – |
| Revenue/Share | – | $2.51 |
| FCF/Share | $-1.92 | – |
Profitability & Margins
| Metric | MAZE | NVAX |
|---|---|---|
| ROE | -29.5% | – |
| ROA | -25.1% | -25.9% |
| ROIC | -28.6% | -37.5% |
| Gross Margin | – | 78.6% |
| Operating Margin | -364.0% | -56.6% |
| Net Margin | -334.0% | -59.9% |
| EBT Margin | -281.7% | -59.3% |
| Tax Rate | – | -1.0% |
Financial Health
| Metric | MAZE | NVAX |
|---|---|---|
| Current Ratio | 18.31x | 2.33x |
| Quick Ratio | – | 2.30x |
| D/E Ratio | 0.17x | – |
| Financial Leverage | 1.17x | – |
| Interest Coverage | – | -12.1x |
| Working Capital | $397M | $441M |
Cash Flow
| Metric | MAZE | NVAX |
|---|---|---|
| Operating Cash Flow | -$107M | -$37M |
| Free Cash Flow | -$107M | – |
| Capital Spending | -$300K | – |
Operational Efficiency
| Metric | MAZE | NVAX |
|---|---|---|
| Asset Turnover | – | 0.43x |
| Receivables Turnover | – | 22.1x |
| Inventory Turnover | – | 8.8x |
| Fixed Assets Turnover | – | 10.8x |
| Days Sales Outstanding | – | 17 days |
| Days Inventory | – | 41 days |
| Payables Period | – | 95 days |
| Cash Conversion Cycle | – | -37 days |
Income Statement
| Metric | MAZE | NVAX |
|---|---|---|
| Total Revenue | – | $414M |
| Operating Income | -$146M | -$234M |
| Net Income | -$134M | -$248M |
| R&D Expense | $122M | $340M |
| SG&A Expense | – | $213M |
| Cost of Goods Sold | – | $89M |
Dividend & Shareholder Information
| Metric | MAZE | NVAX |
|---|---|---|
| Shares Outstanding | 56M | 165M |
| Net Income Growth | – | -158.6% |
| EPS Growth | – | -197.0% |
MAZE vs NVAX: stock comparison and AI forecast
Which is bigger, MAZE or NVAX?
MAZE and NVAX have similar market capitalizations ($1.69B and $1.66B).
Which one does Intratio's AI model rank higher, MAZE or NVAX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.